Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 8;8(11):9764-9774.
doi: 10.1021/acsomega.3c00056. eCollection 2023 Mar 21.

Therapeutic Role of ELOVL in Neurological Diseases

Arif Jamal Siddiqui  1   2 , Sadaf Jahan  3 , Swati Chaturvedi  4 , Maqsood Ahmed Siddiqui  5 , Mohammed Merae Alshahrani  6 , Abdelmushin Abdelgadir  1   2 , Walid Sabri Hamadou  1   2 , Juhi Saxena  7 , Bharath K Sundararaj  8 , Mejdi Snoussi  1   2 , Riadh Badraoui  1   2 , Mohd Adnan  1   2
Affiliations
Review

Therapeutic Role of ELOVL in Neurological Diseases

Arif Jamal Siddiqui et al. ACS Omega. .

Abstract

Fatty acids play an important role in controlling the energy balance of mammals. De novo lipogenesis also generates a significant amount of lipids that are endogenously produced in addition to their ingestion. Fatty acid elongation beyond 16 carbons (palmitic acid), which can lead to the production of very long chain fatty acids (VLCFA), can be caused by the rate-limiting condensation process. Seven elongases, ELOVL1-7, have been identified in mammals and each has a unique substrate specificity. Researchers have recently developed a keen interest in the elongation of very long chain fatty acids protein 1 (ELOVL1) enzyme as a potential treatment for a variety of diseases. A number of neurological disorders directly or indirectly related to ELOVL1 involve the elongation of monounsaturated (C20:1 and C22:1) and saturated (C18:0-C26:0) acyl-CoAs. VLCFAs and ELOVL1 have a direct impact on the neurological disease. Other neurological symptoms such as ichthyotic keratoderma, spasticity, and hypomyelination have also been linked to the major enzyme (ELOVL1). Recently, ELOVL1 has also been heavily used to treat a number of diseases. The current review focuses on in-depth unique insights regarding the role of ELOVL1 as a therapeutic target and associated neurological disorders.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Role of ELOVL1 in X-ALD and other neurological diseases.
Figure 2
Figure 2
Therapeutic inhibitors of ELOVL1.
See this image and copyright information in PMC

References

    1. Nie L.; Pascoa T. C.; Pike A. C.; Bushell S. R.; Quigley A.; Ruda G. F.; Chu A.; Cole V.; Speedman D.; Moreira T.; et al. The structural basis of fatty acid elongation by the ELOVL elongases. Nature structural & molecular biology 2021, 28 (6), 512–520. 10.1038/s41594-021-00605-6. - DOI - PMC - PubMed
    1. Lamari F.; Mochel F.; Saudubray J.-M. An overview of inborn errors of complex lipid biosynthesis and remodelling. Journal of inherited metabolic disease 2015, 38, 3–18. 10.1007/s10545-014-9764-x. - DOI - PubMed
    1. Jung U. J.; Choi M.-S. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. International journal of molecular sciences 2014, 15 (4), 6184–6223. 10.3390/ijms15046184. - DOI - PMC - PubMed
    1. Erdbrügger P.; Fröhlich F. The role of very long chain fatty acids in yeast physiology and human diseases. Biological chemistry 2020, 402 (1), 25–38. 10.1515/hsz-2020-0234. - DOI - PubMed
    1. Garcia-Cazorla À.; Mochel F.; Lamari F.; Saudubray J. M. The clinical spectrum of inherited diseases involved in the synthesis and remodeling of complex lipids. A tentative overview. J. Inherit Metab Dis 2015, 38 (1), 19–40. 10.1007/s10545-014-9776-6. - DOI - PubMed